Project Grant R01CA300091
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $692K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $442,816 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2027. This award funds research interrogating erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia (AML). The project addresses a critical clinical gap by investigating how TP53-mutated AML patients...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. This award supports fundamental research to understand the immunoevasion mechanisms employed by precancerous stem cells in basal-like breast cancer (BLBC), with the goal of developing immunoprevention strategies to intercept progression to aggressive...
- Federal Grant Award Summary The National Cancer Institute awarded a $168,000 Project Grant to Albert Einstein College of Medicine under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The grant supports research to elucidate the mechanisms of pancreatic ductal adenocarcinoma (PDAC) dormancy and minimal residual disease (MRD), with particular focus on identifying and validating therapeutic targets. The research will investigate the role...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $672,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2027. The award supports research investigating a novel synthetic lethal vulnerability in anaplastic thyroid cancer through inhibition of one-carbon metabolism. This two-year research initiative will be conducted at the institution's...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded Columbia University's Health Sciences Division a $501,422 Project Grant effective May 1, 2026, through April 30, 2031, to advance novel synthetic lethal (SL) therapeutic targets in cancer. The research focuses on validating the PELOTA (PELO) and HBS1-like translational GTPase (HBS1L) ribosome rescue complex as a synthetic lethal target for two distinct cancer subtypes:...